ABSTRACT
Abstract BACKGROUND: Endoscopic thoracic sympathectomy is the definitive surgical treatment for hyperhidrosis and a nationwide study has suggested that cultural and socioeconomic factors play a role in the numbers of operations performed. Thus, there is a need to evaluate local data in order to understand the local epidemiology and trends in hyperhidrosis treatment. OBJECTIVE: To study the epidemiology of sympathectomy for treating hyperhidrosis in São Paulo, the largest city in Brazil. DESIGN AND SETTING: Population-based retrospective cross-sectional study. METHODS: Data on sympathectomies for treating hyperhidrosis between 2008 and 2018 were assessed from the database of the Municipal Health Department of São Paulo, Brazil. RESULTS: 65.29% of the patients were female, 66.2% were aged between 20 and 39 years and 37.59% had registered with addresses outside São Paulo. 1,216 procedures were performed in the city of São Paulo from 2008 to 2018, and 78.45% of them were in only two public hospitals. The number of procedures significantly declined over the years (P = 0.001). 71.63% of the procedures were associated with 2-3 days of hospital stay, only 78 intensive care unit days were billed and we did not observe any intra-hospital death. CONCLUSION: The profile of patients operated on in São Paulo (young women) is similar to that described in other populations. Sympathectomy is a very safe procedure, with no mortality in our series. There was a decreasing trend in the number of surgeries over the years.
ABSTRACT
OBJECTIVES: Studies have identified correlations between the psychological characteristics of individuals with primary hyperhidrosis (HH), the degree of sweating, and the quality of life (QoL). This study aimed to evaluate the prevalence of anxiety and depression symptoms in patients with HH before and after oxybutynin treatment. METHODS: Data were collected from 81 patients. Palmar or axillary HH was the most frequent complaint (84.0%). All patients were evaluated before the medication was prescribed and after five weeks of treatment. The Beck Depression Inventory and Beck Anxiety Inventory were used to evaluate depression and anxiety. RESULTS: Improvement in HH occurred in 58 patients (71.6%), but there was no improvement in 23 patients (28.4%). The QoL before treatment in all patients was either "poor" or "very poor." Patients who experienced improvement in sweating rates also experienced a greater improvement in QoL than patients who did not experience improvement in sweating at the main site (87.9% vs. 34.7%) (p<0.001). A total of 19.7% of patients showed an improvement in their level of depression, and a total of 46.9% of patients exhibited improvements in their level of anxiety. A significant correlation was observed between sweating and anxiety (p=0.015). CONCLUSION: Patients with HH who experienced improvements in sweating immediately after treatment with oxybutynin exhibited small improvements in their levels of depression and significant improvements in their levels of anxiety and QoL.
Subject(s)
Humans , Quality of Life , Hyperhidrosis/drug therapy , Anxiety , Sweating , Treatment Outcome , Muscarinic Antagonists , Depression/drug therapy , Depression/epidemiology , Mandelic AcidsABSTRACT
Abstract Hyperhidrosis (HH) is characterized by sweating exceeding the amount necessary to meet the thermal regulation and physiological needs of the body. Approximately 9.41% of individuals with HH have craniofacial hyperhidrosis (FH). The present study aims to review the most current data in the literature regarding craniofacial hyperhidrosis, including pathophysiology, diagnosis and clinical presentation, treatment options (clinical and surgical), and outcomes. VATS (videothoracoscopy sympathectomy) is considered the gold standard for definitive treatment of axillary or palmar hyperhidrosis. Recently, several studies have shown the usefulness of clinical treatment with oxybutynin hydrochloride, leading to clinical improvement of HH in more than 70% of users. Both clinical and surgical treatment of craniofacial hyperhidrosis have good results. However, surgical treatment of FH is associated with more complications. Clinical treatment with oxybutynin hydrochloride yields good results and can be the first therapeutic option. When the patient is not satisfied with this treatment and has good clinical conditions, surgical treatment can be used safely.
Resumo A hiperidrose (HH) é caracterizada por transpiração além da quantidade necessária para manter a regulação térmica e as necessidades fisiológicas do corpo. Aproximadamente 9,41% dos indivíduos com HH apresentam hiperidrose craniofacial (FH). Este estudo tem como objetivo revisar os dados mais atuais da literatura sobre FH, incluindo fisiopatologia, diagnóstico e apresentação clínica, opções de tratamento (clínico e cirúrgico) e desfechos. A simpatectomia por videotoracoscopia (VATS) é considerada o padrão-ouro para o tratamento definitivo da hiperidrose axilar ou palmar. Recentemente, vários estudos demonstraram a utilidade do tratamento clínico com cloridrato de oxibutinina, que leva à melhora clínica da HH em mais de 70% dos pacientes. O tratamento clínico e o cirúrgico apresentam bons resultados no tratamento da FH. No entanto, o tratamento cirúrgico da FH apresenta mais complicações. O tratamento clínico com cloridrato de oxibutinina fornece bons resultados e pode ser a primeira opção terapêutica. Quando o paciente não está satisfeito com esse tratamento e mostra boas condições clínicas, o tratamento cirúrgico pode ser usado com segurança.
Subject(s)
Humans , Sympathectomy , Cholinergic Antagonists/therapeutic use , Hyperhidrosis/therapy , Sweating , Botulinum Toxins/therapeutic use , Head , Hyperhidrosis/diagnosis , Hyperhidrosis/physiopathologyABSTRACT
Abstract Objective To compare the results of the standard urotherapy alone and associated with pelvic floor muscle training alone, and in combination with oxybutynin in treatment of nonmonosymptomatic nocturnal enuresis. Methods A total of 38 children aged 5 to 10 years were randomized into three groups: Group I (n=12) that was submitted to standard urotherapy; Group II (n=15), standard urotherapy associated with pelvic floor muscle training; and Group III (n=11), standard urotherapy associated with pelvic floor muscle training and oxybutynin; the treatment lasted 12 weeks. The assessment tools used were playful bladder diary, and a 48-hour bladder diary, before and after treatment. After 2 years, patients were assessed by telephone using a standardized questionnaire. Results The data of children from the three groups were homogeneous at baseline. After 12-week treatment, all children showed improved symptoms and signs of nonmonosymptomatic nocturnal enuresis, but the differences were not significant among the groups. After 2 years, the three groups showed maintenance of treatment results, but no differences among them. Conclusion All treatment modalities were effective regarding improved enuresis and lower urinary tract symptoms, but the sample was not large enough to show differences among groups.
Resumo Objetivo Comparar os resultados da uroterapia padrão isolada e associada ao treinamento dos músculos do assoalho pélvico isoladamente e em combinação com a oxibutinina no tratamento da enurese noturna não monossintomática. Métodos Trinta e oito crianças entre 5 e 10 anos de idade foram randomizadas em três grupos: Grupo I (n=12) realizou uroterapia padrão; Grupo II (n=15) realizou uroterapia padrão associada ao treinamento muscular do assoalho pélvico; e Grupo III (n=11) realizou uroterapia padrão associada ao treinamento muscular do assoalho pélvico e oxibutinina. O tratamento teve duração de 12 semanas. Os instrumentos de avaliação foram diário miccional lúdico e diário miccional de 48 horas, antes e depois do tratamento. Após 2 anos, os pacientes foram avaliados por telefone, usando um questionário padronizado. Resultados Os dados das crianças dos três grupos eram homogêneos no início do estudo. Após 12 semanas de tratamento, todas as crianças apresentaram melhora em relação aos sinais e sintomas de enurese noturna não monossintomática, mas as diferenças não foram significativas entre os grupos. Depois de 2 anos, os resultados do tratamento se mantiveram nos três grupos, mas não houve diferenças entre os grupos. Conclusão As três modalidades de tratamento foram eficazes na melhora da enurese e dos sintomas do trato urinário inferior, mas o tamanho da amostra não foi grande o suficiente para mostrar diferenças entre os grupos.
Subject(s)
Humans , Male , Female , Child, Preschool , Child , Urinary Incontinence , Pelvic Floor/physiology , Exercise Therapy/methods , Nocturnal Enuresis/therapy , Urological Agents/therapeutic use , Mandelic Acids/therapeutic use , Urinary Incontinence/physiopathology , Brazil , Surveys and Questionnaires , Treatment Outcome , Combined Modality Therapy , Nocturnal Enuresis/physiopathology , Muscle Strength/physiology , Muscle Contraction/physiologyABSTRACT
Objective To develop and validate a LC-MS/MS method to quantify oxybutynin in rabbit plasma and evaluate the bioequivalence of self-prepared oxybutynin chloride gel and Gelnique. Methods The plasma sample was submitted to liquid-liquid extraction using methyl t-butyl ether after alkalified by 0.5 mol/L NaOH, with di-phenhydramine as the internal standard. Chromatographic separation was performed on a Kinetex C18column with the mobile phase consisting of 10 mmol/L ammonium acetate(1‰formic acid)-acetonitrile(50 : 50,v/v). Oxy-butynin and diphenhydramine were ionized with an ESI source operated in positive ion mode,and the detected ions were m/z 358→142 (oxybutynin),m/z 256→167(diphenhydramine). The validated method was then applied to the drug determination in rabbit plasma following single dermal topical administration of oxybutynin gel. Results Calibration curve was liner over the concentration range of 1~200 μg/L in rabbit plasma.For quality control samples, the intra-and inter-day precision was in the range of 1.67%~9.79%, and accuracy was within 92.9% to 103%. Self-prepared oxybutynin chloride gel and Gelnique were proved to be bioequivalent. Conclusions It was validated that the LC-MS/MS method is simple,strong specificity and high sensitivity,which could be successfully applied to pharmacokinetic study and bioequivalence evaluation of transdermal oxybutynin formulations in rabbit.
ABSTRACT
ABSTRACT Introduction and objective Indwelling double J ureteral stents are used routinely in the resolution of ureteral obstruction caused by different etiologies. Evaluation of urinary symptoms related to double-J stent, indicate that these affect 73-90% of patients. We conducted a prospective, randomized study, to evaluate the efficacy of tamsulosin, oxybutinin and combination therapy in improving the urinary symptoms. Methods Patients who underwent ureteral stent placement after ureterolithotripsy (total 51), were randomized into three groups: Group I: Tamsulosin 0.4 mg. once per day(17 patients), Group II: Oxybutinin 5 mg. once per day (17 patients), Group III: Tamsulosin+ oxybutynin once per day (17 patients). All the groups received the drugs for three weeks and completed a Spanish validated Ureteral Stent Symptom Questionnaire (USSQ) at day 7 and 21. Results Repeated measures ANOVA showed mean urinary symptom index score was 22.3 vs. 15.5 in group three (p<0.001) at day 7 and 21 respectively. The mean work performance index was 6.6 vs 8.1 (p=0.049) favoring tamsulosin group, the mean sexual score was 0.5 vs 1.5 (p=0.03). Among additional problems the mean was 7.2 vs 6.2 (p=0.03). No significant difference was noted among pain and general health index. No side effects were reported. Conclusions Combination therapy with tamsulosin and oxybutynin improved irritative symptoms and work performance as well as sexual matters. Combination therapy should be considered for patients who complained of stent related symptoms.
Subject(s)
Humans , Male , Female , Adult , Sulfonamides/therapeutic use , Stents/adverse effects , Lower Urinary Tract Symptoms/etiology , Lower Urinary Tract Symptoms/drug therapy , Urological Agents/therapeutic use , Mandelic Acids/therapeutic use , Quality of Life , Time Factors , Ureter , Ureteral Obstruction , Ureteral Obstruction/complications , Ureteral Obstruction/therapy , Single-Blind Method , Prospective Studies , Surveys and Questionnaires , Reproducibility of Results , Analysis of Variance , Treatment Outcome , Drug Therapy, Combination , Lower Urinary Tract Symptoms/prevention & control , Middle AgedABSTRACT
OBJECTIVE: Hyperhidrosis is a common disease, and thoracoscopic sympathectomy improves its symptoms in up to 95% of cases. Unfortunately, after surgery, plantar hyperhidrosis may remain in 50% of patients, and compensatory sweating may be observed in 70%. This clinical scenario remains a challenge. Our objective was to evaluate the effectiveness of oxybutynin in the treatment of persistent plantar hyperhidrosis and compensatory sweating and its effects on quality of life in women after thoracoscopic sympathectomy. METHOD: We conducted a prospective, randomized study to compare the effects of oxybutynin at 10 mg daily and placebo in women with persistent plantar hyperhidrosis. The assessment was performed using a quality-of-life questionnaire for hyperhidrosis and sweating measurement with a device for quantifying transepidermal water loss. Clinicaltrials.gov: NCT01328015. RESULTS: Sixteen patients were included in each group (placebo and oxybutynin). There were no significant differences between the groups prior to treatment. After oxybutynin treatment, there was a decrease in symptoms and clinical improvement based on the quality-of-life questionnaire (before treatment, 40.4 vs. after treatment, 17.5; p = 0.001). The placebo group showed modest improvement (p = 0.09). The outcomes of the transepidermal water loss measurements in the placebo group showed no differences (p = 0.95), whereas the oxybutynin group revealed a significant decrease (p = 0.001). The most common side effect was dry mouth (100% in the oxybutynin group vs. 43.8% in the placebo group; p = 0.001). CONCLUSION: Oxybutynin was effective in the treatment of persistent plantar hyperhidrosis, resulting in a better quality of life in women who had undergone thoracoscopic sympathectomy. .
Subject(s)
Adult , Female , Humans , Young Adult , Hyperhidrosis/drug therapy , Mandelic Acids/therapeutic use , Muscarinic Antagonists/therapeutic use , Sympathectomy/methods , Patient Satisfaction , Quality of Life , Statistics, Nonparametric , Surveys and Questionnaires , Sympathectomy/rehabilitation , Time Factors , Treatment OutcomeABSTRACT
PURPOSE: Anticholinergics are a key element in treating neurogenic detrusor overactivity, but only limited data are available in the pediatric population, thus limiting the application to children even for oxybutynin chloride (OC), a prototype drug. This retrospective study was designed to provide data regarding the efficacy, tolerability, and safety of OC in the pediatric population (0-15 years old) with spinal dysraphism (SD). MATERIALS AND METHODS: Records relevant to OC use for neurogenic bladder were gathered and scrutinized from four specialized clinics for pediatric urology. The primary efficacy outcomes were maximal cystometric capacity (MCC) and end filling pressure (EFP). Data on tolerability, compliance, and adverse events (AEs) were also analyzed. RESULTS: Of the 121 patient records analyzed, 41 patients (34%) received OC at less than 5 years of age. The range of prescribed doses varied from 3 to 24 mg/d. The median treatment duration was 19 months (range, 0.3-111 months). Significant improvement of both primary efficacy outcomes was noted following OC treatment. MCC increased about 8% even after adjustment for age-related increases in MCC. Likewise, mean EFP was reduced from 33 to 21 cm H2O. More than 80% of patients showed compliance above 70%, and approximately 50% of patients used OC for more than 1 year. No serious AEs were reported; constipation and facial flushing consisted of the major AEs. CONCLUSIONS: OC is safe and efficacious in treating pediatric neurogenic bladder associated with SD. The drug is also tolerable and the safety profile suggests that adjustment of dosage for age may not be strictly observed.
Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Drug Evaluation/methods , Mandelic Acids/adverse effects , Muscarinic Antagonists/adverse effects , Retrospective Studies , Spinal Dysraphism/complications , Treatment Outcome , Urinary Bladder, Neurogenic/drug therapy , Urological Agents/adverse effectsABSTRACT
OBJECTIVE: In vivo study on the oxybutynin hydrochloride (OXB) ethosomal gel in rabbits was carried out to obtain pharmacokinetic parameters in comparison to contrast gel. METHODS: After transdermal administration in rabbits of the OXB ethosomal gel and contrast gel respectively, OXB in the plasma was determined by HPLC-MS, the pharmacokinetic parameters were calculated with DAS 2.1.1. RESULTS: Dose of OXB for 20 mg in the ethosomal gel and for 50 mg in contrast gel transdermal delivery, the AUC0→48 of ethosomal gel and contrast gel were 597.63, 518.40 ng · h · mL-1, ρmax were 27.91, 29.81 ng · mL-1, and tmax were 6.67, 4.67 h respectively. A relative bioavailability of OXB ethosomal gel was 288.4% compared with contrast gel. CONCLUSION: In vivo experiments indicate that the OXB ethosomal gel not only reduce the drug dosage, but also show good bioavailability in rabbits.
ABSTRACT
The aim of the present study was to formulate oxybutynin in a relatively stable and more acceptable and bioavailable dosage form. Gels and patches were formulated according to the standard methods. The prepared formulations were tested for their hygroscopicity, content uniformity, weight variation and tensile strength. Also the release profile and the stability of patches were determined. The results showed that the amount of humidity absorbed by and F19 was 9.21±0.199 and 9.51±0.306 respectively. The results of tensile strength measurement showed 1.97 and 2.55 g. cm-2 for formulation F5 and F19, respectively. Statistical analysis showed that F5 was significantly more flexible than F19. Regarding their content uniformity, there was the maximum value for both formulations and no significant difference was shown. The results presented in the present study suggest that transdermal patches containing oxybutynin HCl may produce acceptable systemic concentration for therapeutic effect.
ABSTRACT
PURPOSE: Nocturia has been one of the most bothersome symptoms in benign prostatic hyperplasia (BPH) patients. Therefore, the authors evaluated the effect of tolterodine and oxybutyninin on nocturia in BPH patients. MATERIALS AND METHODS: From September 2006 to March 2007, 82 patients who presented over than 2 in nocturnal bladder capacity index (NCBI) in spite of having alpha blockers for 6 months were enrolled. Group I (n=38) took alpha blocker with tolterodine, group II (n=44) took alpha blocker with oxybutynin. The number of their nocturia episodes was separately evaluated by the time before and after the medication. The complications were assessed using a questionnaire. RESULTS: The number of nocturia episodes decreased by at least 1 in 68.4% (26/38), 84.1% (37/44) of patients in group I, II, respectively, and decreased by 2 or more, 1 and were unchanged or increased were 36.8, 31.6, 31.6% in group I patients and 45.5, 38.6, 15.9% in group II patients, respectively. In baseline nocturia > or =6 group, the nocturia decreased by 1 or more in 66.7%, 77.8% in group I, II, respectively. Adverse events, including dry mouth, dizziness, headache, etc, occurred in 21.1% (8/38) in group I and 27.3% (12/44) in group II patients. The complications between two groups showed no significant differences. CONCLUSIONS: Alpha blockers with tolterodine or oxybutynin can be effectively combined as a treatment option for patients with BPH complaining of unresolved nocturia.
Subject(s)
Humans , Dizziness , Headache , Mouth , Nocturia , Prostatic Hyperplasia , Surveys and Questionnaires , Urinary Bladder , Tolterodine TartrateABSTRACT
PURPOSE: The aim of this study was to investigate the efficacy and tolerability of extended-release oxybutynin(oxybutynin ER) in children with a neurogenic bladder. MATERIALS AND METHODS: Fifty-four patients(21 myelomeningocele and 33 lipomyelomeningocele) with a neurogenic bladder were enrolled in the study. We reviewed the medical records and performed a telephone interview. The treatments were changed from immediate-release oxybutynin (oxybutynin IR) or other anticholinergics to oxybutynin ER from August to December 2006. The mean age of the study patients was 11.1 years (range 4 to 18 years) and the mean body weight was 37.9kg(range 16.2 to 72.0kg). All patients were asked about the effectiveness, side effects and compliance with the medication. The number of voids, volume of urine per void or clean intermittent catheterization(CIC) and number of incontinence episodes were also evaluated. RESULTS: The mean duration of oxybutynin ER treatment was 16.3 weeks (range 7-25 weeks). Twenty-six patients(48.1%) responded they had improvement in voiding symptoms. Among the patients, there was a significant reduction in the number of incontinence episodes(from 3.3 to 1.3, p<0.001) with the change in medications. The number of voids or CIC per 24 hours and the maximum volume of urine per void or CIC did not show a significant change. Another twenty-eight patients(51.9%) responded that the improvements were maintained. Among these patients, there were no significant changes of the medications. Only five patients (9.3%) changed their medication because of the side effects. CONCLUSIONS: The results of this study showed that the extended-release oxybutynin was effective and well tolerated in children with a neurogenic bladder.
Subject(s)
Child , Humans , Body Weight , Cholinergic Antagonists , Compliance , Interviews as Topic , Medical Records , Meningomyelocele , Urinary Bladder, NeurogenicABSTRACT
AIM: To study the absorption and distribution characteristics of oxybutynin (OXY) oral tablet and transdermal gel. METHODS: A single dose of 0.1 g OXY transdermal gel (2 mg OXY) was applied to abdominal area about 4 cm2 and 0.5 mg immediate-release tablet was orally given to 48 rats in a randomized, open-label, control design test. The plasma, bladder and liver tissue were collected, disposed and analyzed and OXY pharmacokinetic parameters were calculated and evaluated. RESULTS: The Cmax of OXY transdermal gel and oral tablets in bladder are approximately 800 and 70 times higher than those in plasma. The plasma half life of OXY gel delayed 5.99 h, tablets 2.18 h. CONCLUSION: OXY gel show better pharmacokinetic properties, characterized with long half life and high target organ concentrations than those of tablets.
ABSTRACT
BACKGROUND: The oxybutynin is an anticholinergic agent that binds to muscarinic receptors of bladder muscle promoting an antispasmodic effect. As a consequence there is an increase in bladder capacity, reduction in frequency and a blockade in the initial stimuli of miction. OBJECTIVE: To verify the action of oxybutynin on bladder overactivity due to hemorrhagic cystitis. METHODS: Hemorrhagic cystitis was provoked through an intraperitoneal injection of 200mg/kg of cyclophosphamide in 10 female rats, weighting 200-250g, 24h before the experiment. The control group of 5 female rats received an intraperitoneal injection of 0.5ml of saline. In the experiment the animals were anesthetized with 1.25mg/kg of urethane followed by a cystostomy with a P-50 catheter connected in Y to an infusion pump (rate of infusion - 0.3ml/min) and to a polygraph to register bladder pressure. The parameters studied were: frequency of bladder contraction (Fc), contraction intensity (Ci), time of bladder filling (Tf) and contraction (Tc), and vesical capacity (Vc) (Tf x flow). We determined the mean value for each parameter following of 10min of observation. After these determinations all rats received 71mg/kg of oxybutynin chloride through nasogastric tubing and 1h afterward the measures were repeated. The data were compared with the Kruskal-Wallis test considering significant a p 0.05. RESULTS: A comparison both groups (control versus experimental) before the use of oxybutynin showed the following values of p: Fc - 0.007; Ci - 0.0002; Tf - 0.768; Tc - 0.492; Vc - 0.055. After the use of oxybutynin the corresponding values were: Fc - p=0.055; Ci - p=0.0002; Tf - 0.957; Tc - p=0.181; Vc - p=0.206. CONCLUSION: The oxybutynin chloride was able to control bladder overactivity expressed by a significant reduction in frequency, but no changes in other parameters.
INTRODUÇÃO: A oxibutinina atua como agente anticolinérgico que tem ação anti-muscarínica e, principalmente, ação antiespasmódica na musculatura lisa vesical. Assim, ela causa aumento da capacidade vesical e diminui a frequência miccional e bloqueia o estímulo inicial da micção. OBJETIVO: Verificar se a oxibutinina atua sobre a hiperatividade vesical causada pela cistite hemorrágica, dependente do óxido nítrico. MÉTODOS: Foram estudados dois grupos de animais. O controle com 5 ratas e o experimental com 10 ratas, cujos pesos variaram entre 200g a 250g. A cistite hemorrágica foi provocada pela injeção intraperitoneal de ciclofosfamida 200mg/kg, na véspera do experimento. Após 24 horas, as ratas foram anestesiadas com uretana 1,25mg/kg. A seguir, foi feita cistostomia com cateter P-50. Esse cateter foi conectado em Y a uma bomba de infusão contínua com fluxo de água de 0,3ml/min e a um polígrafo para o registro da cistometria. O registro cistométrico foi feito com a velocidade do papel de 0,05cm/seg, com sensibilidade de 20 e calibração para um curso de 60mm para uma pressão de 100mmHg. Os parâmetros estudados foram: freqüência de contração (Fc), intensidade das contrações (Ic), tempo de enchimento vesical (Te), tempo de contração vesical (Tc) e capacidade vesical (Cv), que foi determinado pelo Te x Fluxo. Esses parâmetros foram determinados por suas médias durante o período de observação de 10 min. Após o registro, foi infundido por gavagem 71 mg/kg de cloridato de oxibutinina. Uma hora depois foi feita nova cistometria. A análise estatística foi feita pelo método de Kruskal-Wallis que comparou os valores do grupo controle com o experimental. O p foi considerado significante quando menor que 0,05. RESULTADOS: A comparação entre os dois grupos dos parâmetros estudados antes da infusão do cloridrato de oxibutinina mostrou: Fc - p=0,007; Ic - p=0,0002; Te - p=0,768; Tc - p=0,492; Cv - p=0,056 A comparação dos parâmetros estudados depois da droga mostrou: Fc - p= 0,055; Ic - p=0,0002; Te - p=0,957; Tc - p=0,181; Cv - p=0,206. CONCLUSÕES: O cloridrato de oxibutinina nesse modelo experimental atuou de forma a alterar somente a freqüência das miccções, controlando a hiperatividade e não promovendo alterações nos demais parâmetros estudados.
ABSTRACT
PURPOSE: Unstable bladder has been known to be one of the reasons for the genesis and persistance of primary vesicoureteral reflux(VUR) in children. And treatment of unstable bladder by anticholinergic agent may contribute to the resolution of primary VUR. We evaluated the effect of an anticholinergic agent(oxybutynin) on the resolution of primary VUR in children with different toilet training and voiding functions. METHODS: 152 children with persistant primary VUR after one year of follow up were randomly assigned to the oxybutynin group(n=59, oxybutynin 0.2 mg/kg twice daily) and the control group(n=93, no oxybutynin) at Ewha Womans University Mok-Dong Hospital from October 1996 to April 2002. The resolution rate of the VUR and the difference according to the status of toilet training and voiding dysfunction were analyzed. Statistical analysis was done by the Chi-square test and a P-value of less than 0.05 was considered as significant. RESULTS: VUR was resolved in 49.2%, improved in 20.3% and not changed in 30.5% in the oxybutynin group(n=59) which was not significantly different to 45.2%, 16.1%, 38.7% in the control group(n=93), respectively. In the non-toilet trained young children, VUR was resolved in 50.0%, improved in 23.5% and not changed in 26.5% in the oxybutynin group(n=34) which was not significantly different to 44.2%, 19.2%, 36.6% in the control group(n=52), respectively. In the toilet trained older children, VUR was resolved in 48.0%, improved in 16.0% and not changed in 36.0% in the oxybutynin group(n=25) which was not significantly different to 46.3%, 12.2%, 41.5% in the control group(n=41), respectively. In the toilet trained older children with no voiding dysfunction, VUR was resolved in 33.3%, improved in 11.1% and not changed in 55.6% in the oxybutynin group(n=9) which was not significantly different to 53.6 %, 10.7%, 35.7% in the control group(n=28), respectively. In the toilet trained older children with voiding dysfunction, VUR was resolved in 56.3%, improved in 18.7% and not changed in 25.0% in the oxybutynin group(n=16), which looked higher than 30.7%, 15.4%, 53.9% in the control group(n=13), respectively, but these were not significantly different either. CONCLUSION: Oxybutynin was not effective in the resolution of primary VUR in non-toilet trained young children and toilet trained older children. Oxybutynin showed slightly higher tendency of reflux resolution in toilet-trained older children with voiding dysfunction but the difference was not statistically significant. Judicious use of oxybutynin is required in selected older children with VUR and voiding dysfunction.
Subject(s)
Child , Female , Humans , Follow-Up Studies , Toilet Training , Urinary Bladder , Vesico-Ureteral RefluxABSTRACT
PURPOSE: Unstable bladder has been known to be one of the reasons for the genesis and persistance of primary vesicoureteral reflux(VUR) in children. And treatment of unstable bladder by anticholinergic agent may contribute to the resolution of primary VUR. We evaluated the effect of an anticholinergic agent(oxybutynin) on the resolution of primary VUR in children with different toilet training and voiding functions. METHODS: 152 children with persistant primary VUR after one year of follow up were randomly assigned to the oxybutynin group(n=59, oxybutynin 0.2 mg/kg twice daily) and the control group(n=93, no oxybutynin) at Ewha Womans University Mok-Dong Hospital from October 1996 to April 2002. The resolution rate of the VUR and the difference according to the status of toilet training and voiding dysfunction were analyzed. Statistical analysis was done by the Chi-square test and a P-value of less than 0.05 was considered as significant. RESULTS: VUR was resolved in 49.2%, improved in 20.3% and not changed in 30.5% in the oxybutynin group(n=59) which was not significantly different to 45.2%, 16.1%, 38.7% in the control group(n=93), respectively. In the non-toilet trained young children, VUR was resolved in 50.0%, improved in 23.5% and not changed in 26.5% in the oxybutynin group(n=34) which was not significantly different to 44.2%, 19.2%, 36.6% in the control group(n=52), respectively. In the toilet trained older children, VUR was resolved in 48.0%, improved in 16.0% and not changed in 36.0% in the oxybutynin group(n=25) which was not significantly different to 46.3%, 12.2%, 41.5% in the control group(n=41), respectively. In the toilet trained older children with no voiding dysfunction, VUR was resolved in 33.3%, improved in 11.1% and not changed in 55.6% in the oxybutynin group(n=9) which was not significantly different to 53.6 %, 10.7%, 35.7% in the control group(n=28), respectively. In the toilet trained older children with voiding dysfunction, VUR was resolved in 56.3%, improved in 18.7% and not changed in 25.0% in the oxybutynin group(n=16), which looked higher than 30.7%, 15.4%, 53.9% in the control group(n=13), respectively, but these were not significantly different either. CONCLUSION: Oxybutynin was not effective in the resolution of primary VUR in non-toilet trained young children and toilet trained older children. Oxybutynin showed slightly higher tendency of reflux resolution in toilet-trained older children with voiding dysfunction but the difference was not statistically significant. Judicious use of oxybutynin is required in selected older children with VUR and voiding dysfunction.
Subject(s)
Child , Female , Humans , Follow-Up Studies , Toilet Training , Urinary Bladder , Vesico-Ureteral RefluxABSTRACT
PURPOSE: The purpose of this study was to evaluate the urodynamic effect of oxybutynin chloride on bladder dysfunction in rats with focal cerebral ischemia. MATERIALS AND METHODS: The cerebral infarction of 8 to 9 week-old male Sprague-Dawley rats was induced by occlusion of the left middle cerebral artery. The control groups received sham operation. At 1, 2 and 4 weeks after operation, cystometrogram (CMG) was performed before and after intravesical instillation of 0.5 ml of oxybutynin chloride (0.005 and 0.05 mg/ml) (n=7). RESULTS: The body weight of cerebral-infarcted (CI) rats was smaller than that of sham-operated rats. Compared to sham-operated rats, CI rats showed a shorter voiding interval, smaller micturition pressure, smaller voiding volume and more residual urine. in CMG. After intravesical instillation of oxybutynin, CMG showed dose-dependent increase of voiding interval and functional bladder volume and decrease of peak micturition pressure. The effects of oxybutynin on CI rats were more prominant than that of sham-operated rats. CONCLUSIONS: CI rats showed urinary frequency and decrease of micturition pressure in CMG. The result of this study will be useful for explanation of the detrusor hyperactivity with impaired contractility (DHIC) in patients with cerebral infarction. These results suggest that treatment with intravesical oxybutynin will be an effective alternative treatment of detrusor hyperactivities with cerebral infarction.
Subject(s)
Animals , Humans , Male , Rats , Administration, Intravesical , Body Weight , Brain Ischemia , Cerebral Infarction , Middle Cerebral Artery , Rats, Sprague-Dawley , Urinary Bladder , Urination , UrodynamicsABSTRACT
OBJECTIVE: The aims of this study is to determine the influence of the imbalance between sympathetic and parasympathetic nervous input to colon transit control in spinal cord injured patients and the effect of the anticholinergic medication forneurogenic bladder on colon transit time. METHOD: Eighty-six patients with cervical and thoracic cord injury were enrolled. The colon transit time (CTT) accord ing to the severity and lesion of injury and also the administration routes of oxybutynin were compared by indepen dent t-test. RESULTS: Total CTT was 56.7 hours, with right CTT 16.9 hours, left CTT 21.3 hours and rectosigmoid CTT 18.5 hours. The rectosigmoid CTT of the patients with the lesion at T6 or below were prolonged than that of the patients with the lesion above T6 (p<0.05). According to administration route of oxybutynin, instillation group showed more shortened rectosigmoid CTT than oral route group (p<0.05). CONCLUSION: The imbalance between parasympathetic and sympathetic outflow from the spinal cord has play an im portant role in colon transit control of spinal cord injured patients. The management of neurogenic bowel and bladder considering colon transit time is needed for the effective management of spinal cord injured patients.